Protocols · Cognitive & Mood
PT-141 Sexual Function Protocol
Melanocortin MC4R Agonist | Sexual Desire & Arousal
Typical Dose
1.0–1.75 mg SC PRN
45 min before activity
Route
Subcutaneous
Abdomen or thigh
Cycle
PRN use
Max 1 dose/24h, ≤8 doses/month
Storage
Refrigerate 2–8°C
After reconstitution; protect from light
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-MSH that acts centrally at melanocortin receptors to modulate sexual desire and arousal. Unlike PDE5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 engages the central nervous system pathways that initiate sexual motivation — making it a useful tool in patients whose dysfunction is rooted in desire or arousal deficit rather than purely vasculogenic erectile failure.
This protocol targets adult patients with hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), or mixed-etiology erectile dysfunction in men who have failed or do not tolerate PDE5 inhibitors. It is also used in patients with SSRI-induced sexual dysfunction, post-menopausal desire loss, and idiopathic low libido in younger patients with otherwise normal endocrine workup.
The protocol uses PT-141 as monotherapy on an as-needed basis. The clinical goal is restoration of subjective desire and physiologic arousal response within 1-3 hours of dosing, without daily systemic exposure.
Key Benefits
Restores subjective sexual desire and arousal via central melanocortin pathways, independent of the NO/cGMP axis. Useful in HSDD, FSAD, SSRI-induced dysfunction, and mixed-etiology ED unresponsive to PDE5 inhibitors.
Mechanism of Action
Non-selective melanocortin receptor agonist acting primarily at hypothalamic MC4R to drive dopaminergic and oxytocinergic pro-sexual signaling — upstream of and complementary to PDE5 inhibitor vasodilation.
Molecular Information
Weight
1025.2 Da
Length
7 amino acids (cyclic)
Type
Cyclic heptapeptide; α-MSH analog
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
* Synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH).
Pharmacokinetics
Peak
~1.0 hour post-SC
Half-life
~2.7 hours
Cleared
Renal excretion; clinical effect 4–6 hours
Research Indications
HSDD in Premenopausal WomenEFFECTIVE
FDA-Approved Indication
Approved 2019 (Vyleesi) for acquired, generalized HSDD in premenopausal women.
RECONNECT Trials
Two Phase 3 RCTs demonstrated significant improvement in FSFI desire domain and FSDS-DAO distress scores vs. placebo.
Modest Effect Size
~25% of women achieved clinically meaningful response vs. ~17% on placebo.
SSRI-Induced Sexual DysfunctionEMERGING
Mechanistic Rationale
Bypasses serotonergic suppression of dopaminergic reward by acting directly on hypothalamic melanocortin circuits.
Off-Label Use
Supported by observational data and case series; no large RCTs.
Mixed-Etiology ED in MenEMERGING
PDE5-Refractory Cases
Useful when dysfunction is desire/arousal-driven rather than purely vasculogenic.
Complementary to PDE5i
Central arousal upstream of peripheral NO/cGMP vasodilation; separate dosing by ≥8 hours due to additive BP effects.
Off-Label
Earlier Phase 2 male ED trials discontinued due to BP signal at higher doses; current SC dosing has more favorable profile.
Postmenopausal Desire LossMIXED
Empirical Use
Outside FDA label; supported by mechanistic plausibility and small observational series.
Confounded by Endocrine Status
Workup for estrogen/androgen deficiency recommended before initiation.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Test dose / tolerability | 0.5 mg | Single supervised dose | SC |
| Titration (Weeks 1–2) | 0.75–1.0 mg | PRN, max 1/24h | SC |
| Maintenance (Weeks 3–12) | 1.0–1.75 mg | PRN, ≤8/month | SC |
| Nausea-prone patients | 1.0 mg + ondansetron 4mg ODT | 30 min pre-dose | SC + oral |
| Refractory ED with PDE5i | 1.0–1.5 mg | Separate from PDE5i by ≥8h | SC |
Timing · Inject 45 minutes prior to anticipated sexual activity. Receptive window is 4–8 hours. Do not exceed one dose per 24 hours; cap cumulative use at 8 doses per month to limit hyperpigmentation and cardiovascular exposure.
Peptide Interactions
- PDE5 Inhibitors (sildenafil, tadalafil)— Mechanistically complementary but additive BP effects; separate dosing by ≥8 hours.MONITOR
- Sympathomimetics / Stimulants— Additive hypertensive effect; avoid in uncontrolled HTN.MONITOR
- Naltrexone (oral)— PT-141 slows gastric emptying and may significantly reduce oral naltrexone absorption.AVOID
- Kisspeptin-10— Complementary central pathway for sexual motivation; clinical data limited.SYNERGISTIC
- Oxytocin— Downstream of MC4R signaling; some clinicians combine for arousal/bonding response.SYNERGISTIC
- Melanotan II— Overlapping melanocortin agonism; compounds hyperpigmentation and BP risk.AVOID
- Selank / Semax— No known interaction; may co-address anxiety contributing to dysfunction.COMPATIBLE
- Testosterone replacement— Addresses endocrine and central components of low libido respectively.SYNERGISTIC
How to Reconstitute
- 1
Wash hands; assemble 10 mg PT-141 vial, 2 mL bacteriostatic water, alcohol swabs, and an insulin syringe.
- 2
Allow lyophilized vial and BAC water to reach room temperature.
- 3
Wipe both vial stoppers with fresh alcohol swabs and let air dry.
- 4
Draw 2 mL of bacteriostatic water into a syringe.
- 5
Inject the BAC water slowly down the inner wall of the PT-141 vial — do not spray directly onto the powder.
- 6
Gently swirl (do not shake) until the solution is fully clear. Final concentration: 5 mg/mL.
- 7
Reference dosing: 0.5 mg = 0.10 mL (10 units on U-100 insulin syringe); 1.0 mg = 0.20 mL (20 units); 1.75 mg = 0.35 mL (35 units).
- 8
Label the vial with reconstitution date and concentration.
- 9
Store reconstituted vial refrigerated at 2–8°C; protect from light. Use within 28 days.
- 10
Before each dose, inspect solution for clarity and absence of particulates.
- 11
Inject subcutaneously into abdomen or thigh, rotating sites.
- 12
Discard syringes in an approved sharps container; do not reuse needles.
Quality Indicators
Clear, Colorless Solution
Reconstituted PT-141 should be fully clear with no visible particulates, cloudiness, or color.
Verified COA
Reputable source with third-party HPLC purity ≥98% and mass spec confirmation.
Yellow Tint or Cloudiness
Indicates degradation or contamination — discard the vial.
Visible Particulates
Do not inject; discard and re-reconstitute from a fresh vial.
What to Expect
Onset of subjective desire and arousal 45–90 minutes after injection.
Receptive window of approximately 4–8 hours per dose.
Nausea is common on initial doses (~40% in trials) and typically diminishes with subsequent use; ondansetron pre-treatment helps.
Transient BP elevation of roughly +6/+3 mmHg peaking 2–4 hours post-dose, with mild compensatory HR decrease.
By dose 3, most patients know whether PT-141 works for them.
Week 4: responders report improved frequency of satisfying sexual events and desire domain scores.
Week 8: stable PRN pattern; possible focal hyperpigmentation in heavy users (face, gingiva, breasts), more pronounced in darker Fitzpatrick types.
Week 12: formal decision point on continued use, dose change, or discontinuation.
Effect is independent of the NO/cGMP axis — does not replace PDE5 inhibitors in purely vasculogenic ED.
Inter-individual response variability is substantial; non-response at 1.75 mg after 4–6 well-timed doses warrants discontinuation.
Side Effects & Safety
- Nausea (most common; ~40% on initial doses)
- Flushing and headache
- Transient BP elevation with compensatory bradycardia
- Focal hyperpigmentation with repeated/frequent dosing
- Injection-site reactions
- Fatigue or dizziness in first hours post-dose
- Reduced absorption of concurrent oral medications (slowed gastric emptying)
When to Stop & Call Provider
- Severe or persistent hypertension (systolic >180 or diastolic >110)
- Chest pain, palpitations, or syncope post-dose
- New or rapidly changing pigmented skin lesions
- Signs of allergic reaction (rash, swelling, dyspnea)
- Persistent vomiting unresponsive to antiemetics
- Pregnancy or active attempts to conceive
References
RECONNECT Phase 3 Trials of Bremelanotide for HSDD
Two identical Phase 3 RCTs in premenopausal women with HSDD demonstrated statistically significant improvements in FSFI desire domain and FSDS-DAO Item 13 distress scores with 1.75 mg SC PT-141 PRN vs. placebo. Effect sizes were modest; nausea, flushing, and headache were the most common AEs. Supported 2019 FDA approval as Vyleesi.
Bremelanotide Cardiovascular Safety Pooled Analysis
Pooled analysis across Phase 2/3 trials characterized transient post-dose BP increase of approximately 6/3 mmHg peaking at 2–4 hours, with compensatory HR decrease. Effect was not cumulative across repeated doses; uncontrolled HTN and CV disease remain contraindications.
Melanocortin Receptor Pharmacology and Sexual Function
Review of hypothalamic MC4R signaling in the paraventricular nucleus and medial preoptic area driving pro-erectile and pro-desire responses via downstream dopaminergic and oxytocinergic pathways — providing mechanistic basis for PT-141's effect independent of the NO/cGMP axis.